Company AB Science

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 31/07/2026 +04			After hours 20:15:47
0.5410 ^EUR	+1.88%		0.5410	0.00%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Pharmaceuticals	1.61M	958K	970K	1.07M	1.17M

See all business segments

Geographical breakdown of sales: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	-	-	-	-	955K
outside Europe	-	-	-	-	219K

See all geographic segments

Executive Committee: AB Science

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018
Alexis Bernard PRN	Corporate Officer/Principal	-	-

See AB SCIENCE governance

Composition of the Board of Directors: AB Science

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021
Catherine Johnston-Roussillon BRD	Director/Board Member	68	27/06/2021
Guillemette Latscha BRD	Director/Board Member	-	27/06/2021
Stéphane Ledermann CHM	Chairman	-	07/07/2026

Composition of the Board of Directors

Shareholders: AB Science

Name	Stocks	%	Valuation
UBS Wealth Management SGIIC SA 0.004443 %	3,100	0.004443 %	3 137 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 5.198 %	85,471	5.198 %	32 638 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 4.167 %	64,103	4.167 %	20 081 €

List of AB SCIENCE shareholders

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+1.88%	+5.87%	-63.45%	-86.54%	48.92M
MERCK & CO., INC.	+0.68%	-0.06%	+67.68%	+22.82%	321B
MERCK KGAA	+0.21%	+2.87%	+29.78%	-10.42%	71.5B
HALOZYME THERAPEUTICS, INC.	-1.27%	+0.57%	+37.39%	+91.79%	9.88B
KYOWA KIRIN CO., LTD.	-3.60%	-1.52%	-0.43%	-5.11%	8.7B
SK BIOPHARMACEUTICALS CO., LTD.	+1.80%	-0.88%	-20.84%	-3.30%	4.25B
YUHAN CORPORATION	-0.68%	+2.94%	-38.65%	+11.36%	3.86B
BETTA PHARMACEUTICALS CO., LTD.	+3.08%	-5.35%	-9.43%	+0.75%	3.47B
SUPERNUS PHARMACEUTICALS, INC.	-2.19%	-3.35%	+27.21%	+45.49%	2.65B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.85%	+5.41%	-3.94%	-4.52%	2.23B
Average	+0.09%	+1.83%	+2.53%	+6.23%	42.72B
Weighted average by Cap.	+0.54%	+4.48%	+56.14%	+17.73%